Novartis announced the company’s financial results for the second quarter and first half of 2019.
Our Executive Team talks about innovation highlights from the second quarter of 2019.
Our teams aim to deliver on the promise of cell and gene therapy for patients.
Disclosure of transfers of value to healthcare professionals and support to patient groups in accordance with EFPIA Codes and other local laws and regulations.
[email protected] of the Novartis Foundation and @SteveDavisPATH on how we can achieve #HealthForAll by making digital t… https://t.co/d4rTCYqTSI
#BreakingNews: Novartis receives FDA priority review for investigational biologic therapy for the prevention of… https://t.co/k5LrYrQhpK
NEWS: The Novartis Foundation is sharpening its focus to concentrate fully on reimagining how data, digital and AI… https://t.co/49mJNlpYU9
This site is intended for a global audience.